BofA Securities, Jefferies, Leerink Partners, Evercore ISI and Guggenheim Securities are acting as joint book-running managers for the offering.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PCVX:
- Vaxcyte offering marketed at $50 per share, Bloomberg says
- Vaxcyte announces offering of $500M of common stock and warrants
- Vaxcyte provides update on development of VAX-31 pneumococcal vaccine
- Needham ups Vaxcyte target, adds to Conviction List
- Buy Rating on Vaxcyte: De-Risked VAX-31 Clinical Profile, Strong Cash Position, and Attractive Entry Ahead of 2026 Phase 3 Catalyst